Clinical significance of hormonal receptor status of malignant ovarian tumors

Clinical significance of hormonal receptor status of malignant ovarian tumors

Objectives: To study hormonal receptor status (HRS) of malignant ovarian tumors (MOT) and determine its clinical significance. Patients and Methods: Retrospective analysis of case histories of 284 patients with MOT of different genesis of I–IV stages was carried out; immunohistochemical study of par...

Повний опис

Збережено в:
Бібліографічні деталі
Дата:2014
Автори: Tkalia, I.G., Vorobyova, L.I., Svintsitsky, V.S., Nespryadko, S.V., Goncharuk, I.V., Lukyanova, N.Y., Chekhun, V.F.
Формат: Стаття
Мова:English
Опубліковано: Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України 2014
Назва видання:Experimental Oncology
Теми:
Original contributions
Онлайн доступ:http://dspace.nbuv.gov.ua/handle/123456789/145343
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
Назва журналу:Digital Library of Periodicals of National Academy of Sciences of Ukraine
Цитувати:Clinical significance of hormonal receptor status of malignant ovarian tumors / I.G. Tkalia, L.I. Vorobyova, V.S. Svintsitsky, S.V. Nespryadko, I.V. Goncharuk, N.Y. Lukyanova, V.F. Chekhun // Experimental Oncology. — 2014. — Т. 36, № 2. — С. 125-133. — Бібліогр.: 39 назв. — англ.

Репозитарії

Digital Library of Periodicals of National Academy of Sciences of Ukraine
id irk-123456789-145343
record_format dspace
spelling irk-123456789-1453432019-01-21T01:23:11Z Clinical significance of hormonal receptor status of malignant ovarian tumors Tkalia, I.G. Vorobyova, L.I. Svintsitsky, V.S. Nespryadko, S.V. Goncharuk, I.V. Lukyanova, N.Y. Chekhun, V.F. Original contributions Objectives: To study hormonal receptor status (HRS) of malignant ovarian tumors (MOT) and determine its clinical significance. Patients and Methods: Retrospective analysis of case histories of 284 patients with MOT of different genesis of I–IV stages was carried out; immunohistochemical study of paraffin-embedded tissues. The HRS for serous, mucinous ovarian cancer (OC) and sex cord-stromal tumors (SCST) was studied. The phenotype of tumors by HRS in patients with serous OC was determined; overall and relapse-free survival in these patients was evaluated depending on the tumor HRS. Results: Positive expression of ER has been registered in 66.4% of patients with serous OC, PR — in 63.4%, TR — in 53.0%; in patients with mucinous OC — 88.0; 84.0; 60.0%, respectively. Positive staining of cells of stroma-cellular tumors has been observed in 74.1% of patients for ER and 77.8% — for PR and TR. The highest number of patients with tumor phenotype ER+PR+TR+ has been observed in postmenopause — 52.4%, especially in late postmenopausal period — 39.0%. The lowest percentage of patients with mentioned phenotype has been marked in reproductive age — 20.7%. Most patients of reproductive period had phenotype of tumor ER-PR-TR- (35.1%), in late postmenopause this phenotype has been observed only in 16.2%. The patients with serous OC with the positive tumor HRS demonstrated the low indices of overall and relapse-free survival compared to the patients with receptor-negative tumors con­cerning all steroid hormones (р < 0.05). Conclusions: Positive HRS was registered in serous, mucinous OC and in SCST, high percen­tage of tumors with expression of all receptors of steroid hormones was observed at that. The highest frequency of tumors with positive HRS was recorded in patients with serous OC of late postmenopausal period. The patients with serous OC with receptor-positive tumor phenotype showed the rates of overall and relapse-free survival significantly lower compared to the patients with receptor-negative phenotype of OC. Positive HRS, the same as strong expression of TR in patients with serous OC, is a predictive factor of unfavorable course of tumor process. HRS of MOT can be regarded as the additional criterion for solution of a question concerning application of hormonal therapy as a component of complex treatment for the patients. Key Words: malignant ovarian tumors, serous ovarian cancer, hormonal receptor status, estrogen, progesterone, testosterone receptors, phenotype of tumor. 2014 Article Clinical significance of hormonal receptor status of malignant ovarian tumors / I.G. Tkalia, L.I. Vorobyova, V.S. Svintsitsky, S.V. Nespryadko, I.V. Goncharuk, N.Y. Lukyanova, V.F. Chekhun // Experimental Oncology. — 2014. — Т. 36, № 2. — С. 125-133. — Бібліогр.: 39 назв. — англ. 1812-9269 http://dspace.nbuv.gov.ua/handle/123456789/145343 en Experimental Oncology Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
institution Digital Library of Periodicals of National Academy of Sciences of Ukraine
collection DSpace DC
language English
topic Original contributions
Original contributions
spellingShingle Original contributions
Original contributions
Tkalia, I.G.
Vorobyova, L.I.
Svintsitsky, V.S.
Nespryadko, S.V.
Goncharuk, I.V.
Lukyanova, N.Y.
Chekhun, V.F.
Clinical significance of hormonal receptor status of malignant ovarian tumors
Experimental Oncology
description Objectives: To study hormonal receptor status (HRS) of malignant ovarian tumors (MOT) and determine its clinical significance. Patients and Methods: Retrospective analysis of case histories of 284 patients with MOT of different genesis of I–IV stages was carried out; immunohistochemical study of paraffin-embedded tissues. The HRS for serous, mucinous ovarian cancer (OC) and sex cord-stromal tumors (SCST) was studied. The phenotype of tumors by HRS in patients with serous OC was determined; overall and relapse-free survival in these patients was evaluated depending on the tumor HRS. Results: Positive expression of ER has been registered in 66.4% of patients with serous OC, PR — in 63.4%, TR — in 53.0%; in patients with mucinous OC — 88.0; 84.0; 60.0%, respectively. Positive staining of cells of stroma-cellular tumors has been observed in 74.1% of patients for ER and 77.8% — for PR and TR. The highest number of patients with tumor phenotype ER+PR+TR+ has been observed in postmenopause — 52.4%, especially in late postmenopausal period — 39.0%. The lowest percentage of patients with mentioned phenotype has been marked in reproductive age — 20.7%. Most patients of reproductive period had phenotype of tumor ER-PR-TR- (35.1%), in late postmenopause this phenotype has been observed only in 16.2%. The patients with serous OC with the positive tumor HRS demonstrated the low indices of overall and relapse-free survival compared to the patients with receptor-negative tumors con­cerning all steroid hormones (р < 0.05). Conclusions: Positive HRS was registered in serous, mucinous OC and in SCST, high percen­tage of tumors with expression of all receptors of steroid hormones was observed at that. The highest frequency of tumors with positive HRS was recorded in patients with serous OC of late postmenopausal period. The patients with serous OC with receptor-positive tumor phenotype showed the rates of overall and relapse-free survival significantly lower compared to the patients with receptor-negative phenotype of OC. Positive HRS, the same as strong expression of TR in patients with serous OC, is a predictive factor of unfavorable course of tumor process. HRS of MOT can be regarded as the additional criterion for solution of a question concerning application of hormonal therapy as a component of complex treatment for the patients. Key Words: malignant ovarian tumors, serous ovarian cancer, hormonal receptor status, estrogen, progesterone, testosterone receptors, phenotype of tumor.
format Article
author Tkalia, I.G.
Vorobyova, L.I.
Svintsitsky, V.S.
Nespryadko, S.V.
Goncharuk, I.V.
Lukyanova, N.Y.
Chekhun, V.F.
author_facet Tkalia, I.G.
Vorobyova, L.I.
Svintsitsky, V.S.
Nespryadko, S.V.
Goncharuk, I.V.
Lukyanova, N.Y.
Chekhun, V.F.
author_sort Tkalia, I.G.
title Clinical significance of hormonal receptor status of malignant ovarian tumors
title_short Clinical significance of hormonal receptor status of malignant ovarian tumors
title_full Clinical significance of hormonal receptor status of malignant ovarian tumors
title_fullStr Clinical significance of hormonal receptor status of malignant ovarian tumors
title_full_unstemmed Clinical significance of hormonal receptor status of malignant ovarian tumors
title_sort clinical significance of hormonal receptor status of malignant ovarian tumors
publisher Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
publishDate 2014
topic_facet Original contributions
url http://dspace.nbuv.gov.ua/handle/123456789/145343
citation_txt Clinical significance of hormonal receptor status of malignant ovarian tumors / I.G. Tkalia, L.I. Vorobyova, V.S. Svintsitsky, S.V. Nespryadko, I.V. Goncharuk, N.Y. Lukyanova, V.F. Chekhun // Experimental Oncology. — 2014. — Т. 36, № 2. — С. 125-133. — Бібліогр.: 39 назв. — англ.
series Experimental Oncology
work_keys_str_mv AT tkaliaig clinicalsignificanceofhormonalreceptorstatusofmalignantovariantumors
AT vorobyovali clinicalsignificanceofhormonalreceptorstatusofmalignantovariantumors
AT svintsitskyvs clinicalsignificanceofhormonalreceptorstatusofmalignantovariantumors
AT nespryadkosv clinicalsignificanceofhormonalreceptorstatusofmalignantovariantumors
AT goncharukiv clinicalsignificanceofhormonalreceptorstatusofmalignantovariantumors
AT lukyanovany clinicalsignificanceofhormonalreceptorstatusofmalignantovariantumors
AT chekhunvf clinicalsignificanceofhormonalreceptorstatusofmalignantovariantumors
first_indexed 2023-05-20T17:21:54Z
last_indexed 2023-05-20T17:21:54Z
_version_ 1796153128418017280

Схожі ресурси